What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report Amgen's unaudited financial results for the first quarter ended March 31, 2012, along with its financial position as of that date. It includes a press release detailing these results and the company's use of non-GAAP financial measures.

Why does Amgen present non-GAAP financial measures?

Amgen presents non-GAAP financial measures to provide investors with supplemental information that management believes is useful for analyzing the company's ongoing operational performance and financial condition. These measures exclude certain expenses and charges that are not considered part of core operations or that may fluctuate significantly, thereby facilitating comparisons across different reporting periods.

What specific items are excluded from Amgen's non-GAAP financial measures for Q1 2012?

For the first quarter of 2012, Amgen excluded items such as the 2012 BI Fremont Transaction Expense, the impact of expensing stock options, acquisition-related expenses, amortization of product technology rights, cost-savings initiatives expense, contingent consideration costs, legal expenses, and non-cash interest expense related to convertible notes.

Does this filing provide specific financial figures like revenue or net income?

This 8-K filing itself does not list specific revenue or net income figures in the main body. It states that these details are provided in the press release attached as Exhibit 99.1. Investors would need to refer to that exhibit for the quantitative financial results.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed an 8-K on April 24, 2012, to report its unaudited financial results for the first quarter ended March 31, 2012. The filing primarily consists of a press release detailing these results, which includes both U.S. Generally Accepted Accounting Principles (GAAP) and non-GAAP financial measures. The company emphasizes its use of non-GAAP measures to provide a more comparable view of ongoing operational performance by excluding certain expenses and charges. Key adjustments in the non-GAAP reporting for Q1 2012 include the exclusion of the 2012 BI Fremont Transaction Expense, the impact of expensing stock options, acquisition-related expenses, amortization of acquired product technology rights, cost-savings initiatives expense, contingent consideration costs, legal expenses, and non-cash interest expense on convertible notes. Amgen believes these adjustments offer investors a clearer understanding of core profitability and financial condition, facilitating better comparisons across reporting periods and against industry peers.

Key Highlights

1Amgen announced its unaudited Q1 2012 financial results via an 8-K filing on April 24, 2012.
2The filing includes a press release with both GAAP and non-GAAP financial measures.
3Non-GAAP measures are used to provide supplemental information and facilitate analysis by excluding specific charges.
4Key expenses excluded in non-GAAP calculations for Q1 2012 include transaction expenses related to the Boehringer Ingelheim (BI) Fremont facility, stock option expensing, acquisition costs, and amortization of acquired intangible assets.
5The company also excluded costs related to cost-savings initiatives, contingent considerations, legal proceedings, and non-cash interest on convertible notes from its non-GAAP figures.
6Amgen believes these non-GAAP adjustments offer a better view of ongoing operational performance and financial condition.
7The filing includes a comparison of Q1 2012 non-GAAP results with similar adjustments made for Q1 2011.

AMGEN INC 8-K Report, Financial Results (Apr 24, 2012)

Summary

Key Highlights

Frequently Asked Questions